

## References

### I-214

1. Reblozyl [package insert]. Summit, NJ: Celgene Corporation, 04/2020.
2. Piga A, Perrotta S, Gamberini MR, et al. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with  $\beta$ -thalassemia. *Blood*. 2019;133(12):1279-1289.
3. Clinical Pharmacology™ 2021. Tampa FL: Gold Standard, Inc. Luspatercept.
4. Micromedex DrugDex Compendium®. 2021. Luspatercept.
5. Fenaux P, Platzbecker GJ, Mufti G, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. *N Engl J Med*. 2020;382:140-51.
6. Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent  $\beta$ -thalassemia. *N Engl J Med*. 2020;382:1219-31.
7. Luspatercept-aamt In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated December 9, 2019.